485 related articles for article (PubMed ID: 16364920)
1. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Garnett MJ; Rana S; Paterson H; Barford D; Marais R
Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
[TBL] [Abstract][Full Text] [Related]
2. RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
[TBL] [Abstract][Full Text] [Related]
3. Regulation and role of Raf-1/B-Raf heterodimerization.
Rushworth LK; Hindley AD; O'Neill E; Kolch W
Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
[TBL] [Abstract][Full Text] [Related]
4. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
5. B-Raf and C-Raf signaling investigated in a simplified model of the mitogenic kinase cascade.
Robubi A; Mueller T; Fueller J; Hekman M; Rapp UR; Dandekar T
Biol Chem; 2005 Nov; 386(11):1165-71. PubMed ID: 16307482
[TBL] [Abstract][Full Text] [Related]
6. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
7. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Emuss V; Garnett M; Mason C; Marais R
Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
[TBL] [Abstract][Full Text] [Related]
8. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
9. Nuclear magnetic resonance and molecular dynamics studies on the interactions of the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins.
Terada T; Ito Y; Shirouzu M; Tateno M; Hashimoto K; Kigawa T; Ebisuzaki T; Takio K; Shibata T; Yokoyama S; Smith BO; Laue ED; Cooper JA
J Mol Biol; 1999 Feb; 286(1):219-32. PubMed ID: 9931261
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
Kanno N; Lesage G; Phinizy JL; Glaser S; Francis H; Alpini G
Hepatology; 2002 Jun; 35(6):1329-40. PubMed ID: 12029618
[TBL] [Abstract][Full Text] [Related]
12. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
14. Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes.
Weber CK; Slupsky JR; Herrmann C; Schuler M; Rapp UR; Block C
Oncogene; 2000 Jan; 19(2):169-76. PubMed ID: 10644994
[TBL] [Abstract][Full Text] [Related]
15. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf.
Terai K; Matsuda M
EMBO J; 2006 Aug; 25(15):3556-64. PubMed ID: 16858395
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
18. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
19. The RAF family: an expanding network of post-translational controls and protein-protein interactions.
Yuryev A; Wennogle LP
Cell Res; 1998 Jun; 8(2):81-98. PubMed ID: 9669024
[TBL] [Abstract][Full Text] [Related]
20. Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization.
Yasuda S; Kai M; Imai S; Takeishi K; Taketomi A; Toyota M; Kanoh H; Sakane F
J Biol Chem; 2009 Oct; 284(43):29559-70. PubMed ID: 19710016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
